Navigation Links
Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takeda's DEXILANT®

FREMONT, Calif., March 2, 2011 /PRNewswire/ -- Handa Pharmaceuticals, LLC ("Handa"), a specialty pharmaceutical company based in Fremont, California, today confirmed that its Abbreviated New Drug Application ("ANDA") for Dexlansoprazole Delayed Release Capsules, 60 mg, a generic version of Takeda's DEXILANT®, has been accepted for review by the U.S. Food and Drug Administration ("FDA"). Based upon available information, Handa believes that it is the first applicant to file an ANDA for DEXILANT® containing a Paragraph IV certification, under the provisions of the Hatch-Waxman Act. Should its ANDA for Dexlansoprazole Delayed Release Capsules, 60 mg, be approved by the FDA, Handa believes that the product may be entitled to 180 days of generic market exclusivity.

According to IMS Health, annual sales of DEXILANT® Delayed Release Capsules, 60 mg, in the U.S. were about $300 million for the twelve months ended December 31, 2010.

About Handa Pharmaceuticals, LLC Handa Pharmaceuticals, LLC is a specialty pharmaceutical company that was established in the San Francisco Bay area in November 2005. Handa's executive leadership has a proven track record of developing controlled-release prescription pharmaceutical products that are difficult to formulate. In December 2010, Handa announced that the U.S. Food and Drug Administration ("FDA") had granted tentative approval of the Company's Abbreviated New Drug Application ("ANDA") for Quetiapine Fumarate Extended-Release Tablets, 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg, a generic version of AstraZeneca's SEROQUEL XR®. Handa is the first applicant to file an ANDA for SEROQUEL XR® 50 mg, 150 mg, 200 mg, and 300 mg containing a Paragraph IV certification, under the provisions of the Hatch-Waxman Act. For more information, please visit

Forward-Looking Statements

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Handa's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Handa disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Handa's current expectations depending upon a number of factors affecting Handa's business. These factors include, among others, patents and other intellectual property rights held by competitors and other third parties and the uncertainty of the outcome of litigation related to such patents and intellectual property rights; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the impact of competitive products and pricing; market acceptance of and demand for Handa's products; difficulties or delays in manufacturing; and other risks and uncertainties.

DEXILANT® is a registered trademark of Takeda Pharmaceuticals North America, Inc.

SEROQUEL® and SEROQUEL XR® are registered trademarks of the AstraZeneca group of companies.Company Contact: Stephen CaryExecutive Vice President and COO Handa Pharmaceuticals, LLC(510) 354-2888stephen.cary@handapharma.comhttp://www.handapharma.comThis press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at


SOURCE Handa Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
2. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
3. N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting
4. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
5. Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference
6. Access Pharmaceuticals to Host Update Conference Call for Investors
7. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
8. Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results Conference Call on March 7
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
11. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
Post Your Comments:
(Date:11/26/2015)... --> ... att använda SyMRI för att hitta optimal ... med multipel skleros (MS) eller hjärntumörmetastaser och ... för att kunna använda SyMRI Research Edition ... kan man generera flera konstrastbilder från en ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Therapeutic Drug Monitoring (TDM) ... Competitive Intelligence, Emerging Opportunities"  report to ... ) has announced the addition of ...
(Date:11/26/2015)... ) has announced ... High Viscosity Drugs" report to their offering. ... addition of the "Self Administration of High ... --> Research and Markets ( ) ... Administration of High Viscosity Drugs" report to ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that will ... their purchase of lice treatment product. In addition, customers will receive a complimentary head ... “Finding lice is a sure way to ruin the holidays, so we encourage all ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with ... the 2016 Building Better Radiology Marketing Programs meeting will showcase some ... March 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session ...
(Date:11/27/2015)... Bangalore, Karnataka (PRWEB) , ... November 27, 2015 ... ... the world, Health-E-minds, an innovative online platform for mental health and wellness consultation, ... KleverKid. , This partnership will bridge the knowledge gap experienced by parents and ...
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley from ... boxing style concert posters. This is one of Joplin's most famous and beautiful concert ... the University of Michigan in Ann Arbor. The According to Hawley, "It is hard ...
(Date:11/26/2015)... ON and Cambridge, ON (PRWEB) , ... November ... ... today the availability of a real-time eReferral system for diagnostic imaging in the ... ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical ...
Breaking Medicine News(10 mins):